Published in Vopr Onkol on January 01, 2002
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. Genomics (1992) 9.06
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet (1995) 4.86
Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer (1997) 4.47
Involvement of Brca2 in DNA repair. Mol Cell (1998) 4.41
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet (1997) 4.16
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med (1998) 3.60
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol (2001) 3.35
A clonal marker induced by mutation in mouse intestinal epithelium. Nature (1988) 3.35
Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature (1994) 3.33
Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet (1992) 3.13
Cytogenetic analysis by chromosome painting using DOP-PCR amplified flow-sorted chromosomes. Genes Chromosomes Cancer (1992) 3.03
Development of the pattern of cell renewal in the crypt-villus unit of chimaeric mouse small intestine. Development (1988) 2.97
Mutations truncating the EP300 acetylase in human cancers. Nat Genet (2000) 2.84
An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet (1993) 2.79
Risk models for familial ovarian and breast cancer. Genet Epidemiol (2000) 2.75
DNA "fingerprints" and segregation analysis of multiple markers in human pedigrees. Am J Hum Genet (1986) 2.55
Familial breast cancer. BMJ (1994) 2.54
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet (1997) 2.53
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
Instability of short tandem repeats (microsatellites) in human cancers. Nat Genet (1994) 2.45
A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev (1999) 2.39
Familial gastric cancer: overview and guidelines for management. J Med Genet (1999) 2.38
Derivation of mouse intestinal crypts from single progenitor cells. Nature (1985) 2.31
Deletion of genes on chromosome 1 in endocrine neoplasia. Nature (1987) 2.27
Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res (1998) 2.20
The extent of linkage disequilibrium in four populations with distinct demographic histories. Am J Hum Genet (2000) 2.03
The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene (1989) 2.02
Cell migration pathway in the intestinal epithelium: an in situ marker system using mouse aggregation chimeras. Cell (1985) 2.02
A polymorphic stop codon in BRCA2. Nat Genet (1996) 1.95
Stem-cell organization in mouse small intestine. Proc Biol Sci (1990) 1.93
Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA (1995) 1.83
A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet (2000) 1.80
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol (1997) 1.73
Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group. Am J Hum Genet (1996) 1.72
A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol (1998) 1.70
The arrangement of nucleosomes in nucleoprotein complexes from polyoma virus and SV40. Cell (1977) 1.69
Presymptomatic screening for multiple endocrine neoplasia type 2A with linked DNA markers. The MEN 2A International Collaborative Group. Lancet (1991) 1.68
Paternal origin of new mutations in von Recklinghausen neurofibromatosis. Nature (1990) 1.64
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res (2000) 1.62
Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia. Am J Hum Genet (1997) 1.62
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61
Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet (1997) 1.55
Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol Cell (1999) 1.53
Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res (1999) 1.51
Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. Magn Reson Imaging (2000) 1.47
Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res (1996) 1.47
A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet (1997) 1.46
The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet (1999) 1.45
Inhibition of endogenous tissue alkaline phosphatase with the use of alkaline phosphatase conjugates in immunohistochemistry. J Histochem Cytochem (1981) 1.44
Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med (1997) 1.44
Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Res (1998) 1.36
High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes Cancer (1995) 1.34
A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet (1992) 1.34
Cowden syndrome and Lhermitte-Duclos disease in a family: a single genetic syndrome with pleiotropy? J Med Genet (1994) 1.33
Phophorylation of polyoma and SV40 virus proteins. J Gen Virol (1977) 1.32
Hereditary ovarian cancer. Heterogeneity in age at diagnosis. Cancer (1991) 1.29
Genetic heterogeneity and localization of a familial breast-ovarian cancer gene on chromosome 17q12-q21. Am J Hum Genet (1993) 1.29
Loss of NF1 alleles in phaeochromocytomas from patients with type I neurofibromatosis. Genes Chromosomes Cancer (1992) 1.29
Gross deletions of the neurofibromatosis type 1 (NF1) gene are predominantly of maternal origin and commonly associated with a learning disability, dysmorphic features and developmental delay. Hum Genet (1998) 1.29
Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. J Med Genet (1995) 1.26
Direct examination of the clonality of carcinogen-induced colonic epithelial dysplasia in chimeric mice. J Natl Cancer Inst (1986) 1.24
Expression of E-cadherin, alpha-catenin and beta-catenin in normal ovarian surface epithelium and epithelial ovarian cancers. Histopathology (1998) 1.22
No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis (1999) 1.21
A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Oncogene (1995) 1.21
Apparent human BRCA1 knockout caused by mispriming during polymerase chain reaction: implications for genetic testing. Genes Chromosomes Cancer (2001) 1.16
Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. Am J Hum Genet (1997) 1.16
Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Hum Mol Genet (1997) 1.15
Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst (1992) 1.13
Immunochemical demonstration of the clonal organization of chimaeric mouse epidermis. Development (1987) 1.13
Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis (2000) 1.12
Styl RFLP recognised by a human IRBP cDNA localised to chromosome 10. Nucleic Acids Res (1988) 1.12
A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res (1993) 1.12
Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2. Genes Chromosomes Cancer (1993) 1.11
Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. Int J Cancer (2000) 1.11
Mapping of von Hippel-Lindau disease to chromosome 3p confirmed by genetic linkage analysis. J Neurol Sci (1990) 1.10
Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene (1997) 1.10
Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene (1997) 1.10
Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab (1995) 1.09
Genetic susceptibility to naevi--a twin study. Br J Cancer (1991) 1.09
Complete characterization of a large marker chromosome by reverse and forward chromosome painting. Hum Genet (1992) 1.09
No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer (1998) 1.09
Effect of gamma radiation at high- and low-dose rate on a novel in vivo mutation assay in mouse intestine. Mutagenesis (1989) 1.07
Prognostic factors in non-infiltrating carcinoma of the bladder: a preliminary report. Br J Urol (1982) 1.07
Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer (1999) 1.07
Organ-related differences in binding of Dolichos biflorus agglutinin to vascular endothelium. Dev Biol (1983) 1.06
Immunohistochemical demonstration of H2 antigens in mouse tissue sections. J Histochem Cytochem (1983) 1.06
The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. Am J Hum Genet (1999) 1.06
RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2. Oncogene (1997) 1.05
A frequent hMSH2 mutation in hereditary non-polyposis colon cancer syndrome. Lancet (1995) 1.04
Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr (1995) 1.04
Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene (1995) 1.04
Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur J Surg Oncol (2001) 1.02